Literature DB >> 22743718

Value of the preoperative SOFT-score, P-SOFT-score, SALT-score and labMELD-score for the prediction of short-term patient and graft survival of high-risk liver transplant recipients with a pre-transplant labMELD-score ≥30.

Benedikt Reichert1, Thomas Becker, Tobias J Weismüller, Moritz Kleine, Lea Zachau, Kai Johanning, Frank Lehner, Jürgen Klempnauer, Harald Schrem.   

Abstract

BACKGROUND: The SOFT-score, P-SOFT-score, SALT-score and labMELD-score have been applied for the prediction of survival of liver transplant recipients after transplantation. We analysed the value of these scores for the prediction of short-term survival in high-risk liver transplant recipients with a labMELD-score ≥30. MATERIAL/
METHODS: Retrospective single-centre analysis including 88 consecutive liver transplants in adults between 01.01.2007 and 31.12.2010 with a pretransplant labMELD-score ≥30 and follow-up until the 31.12.2011. Combined and living-related liver transplants were excluded. ROC-curve analysis was used to calculate sensitivity, specificity and overall model correctness of prognostic models.
RESULTS: The P-SOFT-score demonstrated a significant influence on 1-year patient survival (p=0.045, Mann-Whitney-U test). Multivariate Cox regression analysis showed a significant influence of the P-SOFT-score on patient (p=0.013; Exp(B)=1.050; 95%CI: 1.010-1.091) and on graft survival (p=0.023; Exp(B)=1.042; 95%CI: 1.006-1.080). ROC-curve analysis showed areas under the curve (AUROCs) <0.5 for the SOFT-score, P-SOFT-score, SALT-score and the labMELD-score ≥30 for the prediction of 3-month patient and graft survival as well as 1-year patient and graft survival.
CONCLUSIONS: Our results imply that the SOFT-score, P-SOFT-score, SALT-score and labMELD-score ≥30 all have a sensitivity, specificity and overall model correctness that is unable to discriminate short-term survivors from non-survivors in a collective of high-risk liver transplant recipients sufficiently in order to guide clinical decision making in the current German transplant situation with decreasing numbers of deceased liver donors, decreasing donor organ quality and increasingly sick transplant candidates.

Entities:  

Mesh:

Year:  2012        PMID: 22743718     DOI: 10.12659/aot.883218

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  6 in total

1.  Outcomes among older adult liver transplantation recipients in the model of end stage liver disease (MELD) era.

Authors:  Maricar F Malinis; Shu Chen; Heather G Allore; Vincent J Quagliarello
Journal:  Ann Transplant       Date:  2014-09-26       Impact factor: 1.530

2.  High early cardiovascular mortality after liver transplantation.

Authors:  Lisa B VanWagner; Brittany Lapin; Josh Levitsky; John T Wilkins; Michael M Abecassis; Anton I Skaro; Donald M Lloyd-Jones
Journal:  Liver Transpl       Date:  2014-10-24       Impact factor: 5.799

3.  Value and limitations of the BAR-score for donor allocation in liver transplantation.

Authors:  Harald Schrem; Anna-Luise Platsakis; Alexander Kaltenborn; Armin Koch; Courtney Metz; Marc Barthold; Christian Krauth; Volker Amelung; Felix Braun; Thomas Becker; Jürgen Klempnauer; Benedikt Reichert
Journal:  Langenbecks Arch Surg       Date:  2014-09-14       Impact factor: 3.445

4.  Comparison of Different Scoring Systems Based on Both Donor and Recipient Characteristics for Predicting Outcome after Living Donor Liver Transplantation.

Authors:  Yucheng Ma; Qing Wang; Jiayin Yang; Lunan Yan
Journal:  PLoS One       Date:  2015-09-17       Impact factor: 3.240

5.  Prognostic limitations of the Eurotransplant-Donor Risk Index in liver transplantation.

Authors:  Benedikt Reichert; Alexander Kaltenborn; Alon Goldis; Harald Schrem
Journal:  J Negat Results Biomed       Date:  2013-12-24

6.  Liver transplantation performed in a SARS-CoV-2 positive hospitalized recipient using a SARS-CoV-2 infected donor.

Authors:  Tommaso Maria Manzia; Carlo Gazia; Ilaria Lenci; Roberta Angelico; Luca Toti; Andrea Monaco; Alessandro Anselmo; Leonardo Baiocchi; Paolo Grossi; Giuseppe Tisone
Journal:  Am J Transplant       Date:  2021-03-17       Impact factor: 9.369

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.